ãã€ãªå»è¬åäŒæ¥ã§ãã MacroGenics, Inc. ã¯ãç±³åœã§ããæ²»ççšã®æäœããŒã¹ã®æ²»çè¬ãçºèŠãéçºããŠããŸããåç€Ÿã®æ¿èªæžã¿è£œåã¯ãååŠçæ³ãšã®äœµçšã§ã以åã« 2 å以äžã®æ HER2 çæ³ãåããè»¢ç§»æ§ HER2 éœæ§ä¹³ããã®æäººæ£è
ã®æ²»çã«é©å¿ã®ããããäžç®æé·å ååå®¹äœ 2 (HER2) åå®¹äœæ®æè¬ã§ãã MARGENZA (margetuximab-cmkb) ã§ããå
ç«è
«çåŠã®è£œååè£ã®ãã€ãã©ã€ã³ã«ã¯ãä¹³ããããã³èé£éããã®æ²»çãç®çãšãã第 II/III çžèšåºè©Šéšãè¡ãããŠããã¢ãã¯ããŒãã«æäœã® Margetuximab ããããŸããå瀟ã¯ãŸããæ¥æ§éªšé«æ§çœè¡ç
ã®æ²»çãç®çãšãã CD123 ããã³ CD3 ãèªèãã DART ååã§ãã Flotetuzumab ãéçºããŠããŸããå瀟ã¯ã転移æ§èé管æå¹³äžç®çããã³è»¢ç§»æ§éå°çްèèºçãæšçãšããæ²»éšçšã¢ãã¯ããŒãã«æäœã¬ããã¡ã³ãªãããB7-H3ãæšçãšããã¢ãã¯ããŒãã«æäœãšãããªããºãããPD-1ããã³ãªã³ãçæŽ»æ§åéºäŒå3ãæšçãšããæ²»éšçšå䟡DARTååããããªãããéçºäžã§ãããããã«ãB7-H3ãçºçŸããåºåœ¢è
«çãæšçãšããæäœè¬ç©è€åäœïŒADCïŒMGC018ãå
ç«ãã§ãã¯ãã€ã³ãPD-1ããã³çްèå·å®³æ§Tãªã³ãçé¢é£ã¿ã³ãã¯è³ª4ãæšçãšããã¢ãã¯ããŒãã«æäœMGD019ãããã³æ§ã
ãªåºåœ¢è
«çã¿ã€ãã§éå°çºçŸããŠãã现è衚é¢ã¿ã³ãã¯è³ªADAM9ãæšçãšããADC IMGC936ãéçºäžã§ãããããã«ãå瀟ã®éå
ç«è
«çåŠèšåºè£œååè£ã«ã¯ãããå
ç«äžå
šãŠã€ã«ã¹ææçްèããã³T现èã®ãšã³ãããŒãã¿ã³ãã¯è³ªãæšçãšããDARTååMGD014ãããã 1 åç³å°¿ç
ã®æ²»çã®ããã®ãããªãºãããèªå·±å
ç«çŸæ£ã®æ²»çã®ããã® CD32B à CD79B DART åå PRV-3279 ãªã©ã§ããIncyte CorporationãZai Lab LimitedãI-Mab BiopharmaãJanssen Biotech, Inc.ãAlligator Bioscience AB (publ) ãšææºããŠããŸããå瀟㯠2000 幎ã«èšç«ãããã¡ãªãŒã©ã³ãå·ããã¯ãã«ã«æ¬ç€Ÿã眮ããŠããŸãã